- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BEAM
Recent news which mentions BEAM
10 Health Care Stocks With Whale Alerts In Today's Session
August 04, 2022
From Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
August 03, 2022
From InvestorPlace
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 01, 2022
From Benzinga
Why Beam Therapeutics Stock Dipped Today
August 01, 2022
From Motley Fool
Why Is Target (TGT) Stock in the Spotlight Today?
August 01, 2022
From InvestorPlace
Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News
August 01, 2022
From InvestorPlace
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 01, 2022
From Benzinga
Will a Recession Cause a Housing Crash in 2022?
July 27, 2022
From InvestorPlace
From Benzinga
From Benzinga
From Benzinga
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage
July 18, 2022
From Benzinga
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
From InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
From InvestorPlace
From Benzinga
From Motley Fool
3 Cathie Wood Stocks That Could Deliver Monster Returns
June 04, 2022
From Motley Fool
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Friday
April 08, 2022
From Benzinga
2 Reasons Why Pfizer Might Crush Moderna in the mRNA Market. And 1 Reason Why Moderna May Stay Ahead.
February 17, 2022
From Motley Fool
2 Exciting Trends That Could Shape Healthcare's Future
February 10, 2022
From Motley Fool
Here's What to Look For in Pfizer's Upcoming Earnings Report
January 25, 2022
From Motley Fool
Why Pfizer's Deal With Beam Therapeutics Is a Smart Move
January 23, 2022
From Motley Fool
Moderna Is Betting on a New Way to Fight Cancer
January 23, 2022
From Motley Fool
From Motley Fool
Why Is Pfizer Teaming Up With Acuitas Therapeutics?
January 22, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.